Moderna Named A Top Employer By Science For The Fourth Consecutive Year

CAMBRIDGE, Mass., October 25, 2018 — Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in Science and Science Careers’ 2018 Top Employers Survey. This is the fourth consecutive year Moderna has been selected and this year the company was ranked 4th. The annual employee survey evaluates companies in biotechnology, biopharmaceutical, pharmaceutical and other related industries in categories such as leadership in innovation, alignment between work culture and values and commitment to social responsibility.

“It is an honor to be recognized as a top employer by Science and to be included amongst this group of industry leaders,” said Stéphane Bancel, CEO at Moderna. “As a mission-driven company, we work to attract exceptional team members who are passionate about delivering on the potential of our mRNA science for patients. Our R&D leadership has built an organization where professional and growth opportunities are matched by a commitment to continuous innovation and scientific excellence, and have fostered our company’s culture of respect for the individual, community and citizenship, and where employee feedback is a core component of decision making.”

Moderna earlier this month introduced a range of enhanced benefits, including 16 weeks of paid parental leave and 16 weeks of caregiver leave, and a sabbatical program that offers four weeks of paid time off after five years of full-time employment with the company. These programs complement Moderna’s existing benefits which include extensive healthcare coverage, paid time off for volunteering and subsidized childcare.

The Science and Science Careers’ 2018 survey findings are based on 8,015 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (63%), Europe (24%), and Asia/Pacific Rim (9%); 93% work in biotechnology, biopharmaceutical, and pharmaceutical companies. The complete feature can be found online on the ScienceCareers.org website and in the October 26, 2018 print issue of Science.

About Moderna

Moderna pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets or underserved areas of medical need. Moderna is developing its innovative mRNA medicines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, through solely controlled programs and collaborations with strategic partners.

Headquartered in Cambridge, Mass., privately held Moderna currently has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. Moderna has been ranked a top biopharma industry employer by Science for the past four years, and in 2017 was selected as a “Top Place to Work” by the Boston Globe. To learn more, visit www.modernatx.com.

Contacts

Moderna

Investors:
Lorence Kim
617-209-5849
lorence.kim@modernatx.com

or

Media:
Jason Glashow
617-674-5648
jason.glashow@modernatx.com